Arch Therapeutics, Inc. (0HHJ.L)
| Chiusura precedente | 0,0706 |
| Aperto | 0,1290 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,1290 - 0,1290 |
| Intervallo di 52 settimane | 0,1290 - 0,1290 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | -0,46 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0240 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarterFRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its reimbursement strategy for the use of AC5® Advanced Wound System (“AC5”), specifically regarding its use in doctor’s offices and
- GlobeNewswire
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound SystemFRAMINGHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that the third interview in the Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound
- GlobeNewswire
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring
Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical efficacy of AC5® Advanced Wound System in acute, chronic, and challenging wounds.FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case reports on the use of
